Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection.
Metabolic and morphologic abnormalities in persons with HIV remain common contributors to stigma and morbidity. Increased abdominal circumference and visceral adiposity were first recognized in the late 1990s, soon after the advent of effective combination antiretroviral therapy. Visceral adiposity is commonly associated with metabolic abnormalities including low HDL-cholesterol, raised triglycerides, insulin resistance, and hypertension, a constellation of risk factors for cardiovascular disease and diabetes mellitus known as "the metabolic syndrome". Medline and conference abstracts were searched to identify clinical research on factors associated with visceral adiposity and randomized studies of management approaches. Data were critically reviewed by physicians familiar with the field. A range of host and lifestyle factors as well as antiretroviral drug choice were associated with increased visceral adiposity. Management approaches included treatment switching and metformin, both of which have shown benefit for insulin-resistant individuals with isolated fat accumulation. Testosterone supplements may also have benefits in a subset of individuals. Supra-physiological doses of recombinant human growth hormone and the growth hormone releasing hormone analog tesamorelin both significantly and selectively reduce visceral fat over 12-24 weeks; however, the benefits are only maintained if doping is continued. In summary, the prevention and management of visceral adiposity remains a substantial challenge in clinical practice.
Moyle
Graeme
G
Chelsea and Westminster Hospital, London, UK. gm@moyleg.demon.co.uk
Moutschen
Michel
M
Martínez
Esteban
E
Domingo
Pere
P
Guaraldi
Giovanni
G
Raffi
François
F
Behrens
Georg
G
Reiss
Peter
P
D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D005081:Exercise Therapy; D013007:Growth Hormone-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D039682:HIV-Associated Lipodystrophy Syndrome / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D050152:Intra-Abdominal Fat / Q000187:drug effects / Q000473:pathology; D008687:Metformin / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012306:Risk
D044966:Anti-Retroviral Agents; D006728:Hormones; D007004:Hypoglycemic Agents; D013007:Growth Hormone-Releasing Hormone; D008687:Metformin; C479538:tesamorelin